JP7038099B2 - ガレクチンのα－Ｄ－ガラクトシド阻害剤 - Google Patents

ガレクチンのα－Ｄ－ガラクトシド阻害剤 Download PDF

Info

Publication number
JP7038099B2
JP7038099B2 JP2019500809A JP2019500809A JP7038099B2 JP 7038099 B2 JP7038099 B2 JP 7038099B2 JP 2019500809 A JP2019500809 A JP 2019500809A JP 2019500809 A JP2019500809 A JP 2019500809A JP 7038099 B2 JP7038099 B2 JP 7038099B2
Authority
JP
Japan
Prior art keywords
deoxy
thio
triazole
galactopyranoside
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019500809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524720A5 (enExample
JP2019524720A (ja
Inventor
ゼッテルベリ、フレドリク
レフレール、ハコン
ニルソン、ウルフ
Original Assignee
ガレクト バイオテック エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ガレクト バイオテック エービー filed Critical ガレクト バイオテック エービー
Publication of JP2019524720A publication Critical patent/JP2019524720A/ja
Publication of JP2019524720A5 publication Critical patent/JP2019524720A5/ja
Application granted granted Critical
Publication of JP7038099B2 publication Critical patent/JP7038099B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
JP2019500809A 2016-07-12 2017-07-09 ガレクチンのα－Ｄ－ガラクトシド阻害剤 Expired - Fee Related JP7038099B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16179060.5 2016-07-12
EP16179060 2016-07-12
PCT/EP2017/067180 WO2018011093A1 (en) 2016-07-12 2017-07-09 Alpha-d-galactoside inhibitors of galectins

Publications (3)

Publication Number Publication Date
JP2019524720A JP2019524720A (ja) 2019-09-05
JP2019524720A5 JP2019524720A5 (enExample) 2021-11-04
JP7038099B2 true JP7038099B2 (ja) 2022-03-17

Family

ID=56411454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019500809A Expired - Fee Related JP7038099B2 (ja) 2016-07-12 2017-07-09 ガレクチンのα－Ｄ－ガラクトシド阻害剤

Country Status (6)

Country Link
US (1) US10988502B2 (enExample)
EP (1) EP3484903A1 (enExample)
JP (1) JP7038099B2 (enExample)
CN (1) CN109563120B (enExample)
CA (1) CA3025866A1 (enExample)
WO (1) WO2018011093A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510692A (ja) * 2018-01-10 2021-04-30 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CN109563119A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
EP3744719B1 (en) * 2018-01-25 2023-06-07 Fujimoto Co., Ltd. Thiophene derivative and use thereof
CA3102155A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
CN113366007A (zh) * 2018-10-15 2021-09-07 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂
CN113286632A (zh) * 2018-10-15 2021-08-20 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂前药
US11447517B2 (en) * 2018-11-21 2022-09-20 Galecto Biotech Ab Galactoside inhibitor of galectins
EP3983423A4 (en) 2019-06-14 2023-07-19 Université Laval SYNTHESIS OF 3-AZIDO-3-DEOXY-D-GALACTOPYRANOSE
WO2021001538A1 (en) * 2019-07-03 2021-01-07 Galecto Biotech Ab Novel galactoside inhibitor of galectins
JP7674276B2 (ja) * 2019-07-03 2025-05-09 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
CN115244045A (zh) * 2019-12-24 2022-10-25 糖模拟物有限公司 抑制半乳凝素-3的c-糖苷酮、醚和醇
CN113943330A (zh) * 2020-07-17 2022-01-18 中国科学院上海药物研究所 一类含糖结构化合物、其制备方法、药物组合物和用途
WO2022136307A1 (en) * 2020-12-22 2022-06-30 Galecto Biotech Ab Novel galactoside inhibitor of galectins
CN117043156A (zh) * 2020-12-28 2023-11-10 格莱克特生物技术公司 半乳糖凝集素的新型半乳糖苷抑制剂
CZ2023132A3 (cs) * 2023-04-04 2024-10-16 Ústav Chemických Procesů Av Čr, V. V. I. Komplexy ruthenia pro inhibici galektinů, způsob jejich výroby a jejich použití

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113569A1 (en) 2004-05-21 2005-12-01 Forskapatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
US20060148712A1 (en) 2000-03-13 2006-07-06 Fu-Tong Liu Monocyte chemoattractant activity of galectin-3
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
JP2018503660A (ja) 2015-01-30 2018-02-08 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
JP2019522007A (ja) 2016-07-12 2019-08-08 ガレクト バイオテック エービー ガレクチンのα−Ｄ−ガラクトシド阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849607B2 (en) 2001-05-09 2005-02-01 Health Research, Inc. Galectin recognized photosensitizers for photodynamic therapy
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
ES2652488T3 (es) 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
EP2620443A1 (en) * 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
IN2015DN02573A (enExample) * 2012-10-31 2015-09-11 Galecto Biotech Ab

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148712A1 (en) 2000-03-13 2006-07-06 Fu-Tong Liu Monocyte chemoattractant activity of galectin-3
WO2005113569A1 (en) 2004-05-21 2005-12-01 Forskapatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
JP2018503660A (ja) 2015-01-30 2018-02-08 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
JP2019522007A (ja) 2016-07-12 2019-08-08 ガレクト バイオテック エービー ガレクチンのα−Ｄ−ガラクトシド阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry，2010年，18(14)，P.5367-5378
Bioorganic & Medicinal Chemistry，2011年，19(10)，P.3280-3287

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510692A (ja) * 2018-01-10 2021-04-30 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤

Also Published As

Publication number Publication date
CA3025866A1 (en) 2018-01-18
US20190225638A1 (en) 2019-07-25
EP3484903A1 (en) 2019-05-22
WO2018011093A1 (en) 2018-01-18
US10988502B2 (en) 2021-04-27
CN109563120B (zh) 2022-12-02
CN109563120A (zh) 2019-04-02
JP2019524720A (ja) 2019-09-05

Similar Documents

Publication Publication Date Title
US10988502B2 (en) Alpha-D-galactoside inhibitors of galectins
JP7216634B2 (ja) ガレクチンのα－Ｄ－ガラクトシド阻害剤
JP7674276B2 (ja) ガレクチンの新規なガラクトシド阻害剤
JP6892859B2 (ja) 新規ガラクトシドによるガレクチン阻害剤
US12497428B2 (en) Galactoside inhibitor of galectins
CN114450282A (zh) 半乳糖凝集素的新型半乳糖苷抑制剂
JP2022524678A (ja) ガレクチンのα－Ｄ－ガラクトシド阻害剤
JP6707548B2 (ja) ガレクチンの新規なガラクトシド阻害剤
JP2022508719A (ja) ガレクチンのガラクトシド阻害剤のプロドラッグ
JP2021510692A (ja) ガレクチンの新規なガラクトシド阻害剤
JP7674275B2 (ja) ガレクチンの新規なガラクトシド阻害剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210726

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220307

R150 Certificate of patent or registration of utility model

Ref document number: 7038099

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees